Virbac stock slips despite strong H1 2026 growth and margin gains

Virbac stock (ISIN FR0000031577) traded lower on Euronext Paris on September 18, 2026 even as the French animal health group reported solid first-half 2026 figures, including 7.4 percent organic revenue growth and an 18.8 percent adjusted EBIT margin at constant exchange rates and scope.

H1 2026 revenue and margins come in strong

According to a PRNewswire release summarized by PRNewswire on September 18, 2026, Virbac generated consolidated revenue of EUR 768.0 million in the first half of 2026, up 7.4 percent at constant exchange rates and scope compared with the first half of 2025.

In the same release, adjusted EBIT for H1 2026 is reported at EUR 144.2 million, corresponding to an adjusted EBIT margin of 18.8 percent, which marks an increase of 0.5 percentage points versus H1 2025, highlighting improved profitability despite foreign exchange headwinds and higher operating expenses.PRNewswire

The PRNewswire summary also notes that net income for the first half of 2026 rose by 5.9 percent to EUR 87.1 million compared with H1 2025, while an increase in net debt to EUR 196 million as of June 2026 from EUR 173 million as of December 2025 reflects normal working capital seasonality.PRNewswire

Segment growth and 2026 guidance at upper end

The first-half performance was broadly based: the PRNewswire report indicates that companion animal revenue grew about 10.0 percent and farm animal revenue about 6.7 percent at constant exchange rates and scope, with the company’s Supercharge platforms, excluding Thyronorm, increasing by around 12 percent at constant exchange rates and scope.PRNewswire

According to the same release, Virbac’s operating margin improvement in H1 2026 was driven by a favorable mix effect on the gross margin, partially offset by higher operating expenses linked to phasing between the first and second halves of the year.PRNewswire

On guidance, the PRNewswire summary states that Virbac confirmed its 2026 outlook at the upper end of the initial range, now targeting full-year organic revenue growth at constant exchange rates and scope between 5.5 percent and 7.5 percent, with management aiming for the upper end, and an adjusted recurring operating income margin of around 17 percent at constant exchange rates and scope.PRNewswire

Analyst reaction and share price pressure

Despite the robust figures and confirmed guidance, market reaction has been cautious. As Ideal-investisseur reported on September 18, 2026, Virbac shares fell 5.5 percent and lagged the SBF 120 index after the half-year publication of September 17, 2026, which highlighted 7.4 percent organic growth and targets confirmed at the upper end of the range.

According to Ideal-investisseur, at a share price of EUR 298.00 the stock’s decline did not prompt a change in recommendation from CIC Market Solutions, which maintained its buy opinion on Virbac with an unchanged price target of EUR 400.00, implying an upside potential of about 34 percent from that EUR 298.00 level.Ideal-investisseur

An earnings call recap from Investing.com on September 18, 2026 similarly notes that Virbac’s revenue rose to EUR 768.0 million and that the adjusted EBIT margin improved to 18.8 percent, yet the shares traded down 2.78 percent to USD 306.00 from a prior close of USD 314.50, near the lower end of a 52-week range between USD 297.00 and USD 385.50.

Virbac stock price on Euronext Paris

Per real-time data cited by Boursorama on September 18, 2026, Virbac shares traded at EUR 310.50 on Euronext Paris, down 1.27 percent at that point. A transcript page on Zonebourse shows Virbac quoted around EUR 310.00 on Euronext Paris in the afternoon of September 18, 2026, corresponding to a modest decline of around 1.4 percent on the day and a year-to-date performance slightly negative.

More news and analyses on Virbac stock